Press release
Uveitis Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight | Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma
Uveitis Clinical Trials
"Uveitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uveitis Market.
The Uveitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for sample report @ https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Uveitis Pipeline Report:
• Uveitis Companies across the globe are diligently working toward developing novel Uveitis treatment therapies with a considerable amount of success over the years.
• Uveitis companies working in the treatment market are Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma, and others, are developing therapies for the Uveitis treatment
• Emerging Uveitis therapies in the different phases of clinical trials are- Laquinimod, EYS606, ESK-001, Baricitinib, TRS01, and others are expected to have a significant impact on the Uveitis market in the coming years.
• In August 2023, Tarsier Pharma, an advanced clinical-stage biotechnology company focused on developing dazdotuftide (previously TRS), a groundbreaking New Chemical Entity for individuals with immune-mediated diseases, has disclosed findings from the TRS4VISION Trial, which investigated noninfectious anterior uveitis. Although the primary endpoint was not achieved, a subsequent analysis of the data reveals an eagerly awaited clinical profile, showcasing a combination of safety and effective resolution of inflammation. This outcome holds promise for the treatment of noninfectious uveitis, particularly in managing uveitic glaucoma.
• In April 2023, The World Health Organization (WHO) has placed Tarsier Pharma Ltd., a late-stage pharmaceutical business, on the INN Recommended List and awarded its first-in-class immunomodulator TRS an International Nonproprietary Name (INN) of "Dazdotuftide."
• In September 2021, A Phase III randomized, active-controlled, double-masked trial was started by Tarsier Pharma to assess the safety and effectiveness of TRS01 eye drops in treating patients with active non-infectious anterior uveitis, including those with uveitic glaucoma.
Uveitis Overview
The illness condition known as uveitis causes inflammation in the eyes. A wide range of disease types together known as uveitis have been estimated to cause 10% of blindness. Acute, intermediate, posterior, and panuveitis are the four main categories of uveitis according to the eye's anatomical involvement.
Get a Free Sample PDF Report to know more about Uveitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Uveitis Drugs Under Different Phases of Clinical Development Include:
• Laquinimod: Active Biotech AB
• EYS606: Eyevensys
• ESK-001: Alumis Inc
• Baricitinib: Eli Lilly and Company
• TRS01: Tarsier Pharma
Uveitis Route of Administration
Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type
Uveitis Molecule Type
Uveitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Uveitis Pipeline Therapeutics Assessment
• Uveitis Assessment by Product Type
• Uveitis By Stage and Product Type
• Uveitis Assessment by Route of Administration
• Uveitis By Stage and Route of Administration
• Uveitis Assessment by Molecule Type
• Uveitis by Stage and Molecule Type
DelveInsight's Uveitis Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Uveitis product details are provided in the report. Download the Uveitis pipeline report to learn more about the emerging Uveitis therapies at:
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Uveitis Therapeutics Market include:
Key companies developing therapies for Uveitis are - Novartis AG, Bausch Health Inc., AbbVie Inc., Eyegate Pharmaceuticals, Inc., Alimera Science Inc., EyePoint Pharmaceuticals, Santen Pharmaceuticals, Clearside Biomedical inc., and others.
Uveitis Pipeline Analysis:
The Uveitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Uveitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uveitis Treatment.
• Uveitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uveitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uveitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Uveitis drugs and therapies-
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Uveitis Pipeline Market Drivers
• Increasing Prevalence of Uveitis, increase in Research and developmental Activities are some of the important factors that are fueling the Uveitis Market.
Uveitis Pipeline Market Barriers
• However, high Cost associated with the treatment, lack of skilled professionals and other factors are creating obstacles in the Uveitis Market growth.
Scope of Uveitis Pipeline Drug Insight
• Coverage: Global
• Key Uveitis Companies: Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma, and others
• Key Uveitis Therapies: Laquinimod, EYS606, ESK-001, Baricitinib, TRS01, and others
• Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies
• Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers
Request for Sample PDF Report for Uveitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Uveitis Report Introduction
2. Uveitis Executive Summary
3. Uveitis Overview
4. Uveitis- Analytical Perspective In-depth Commercial Assessment
5. Uveitis Pipeline Therapeutics
6. Uveitis Late Stage Products (Phase II/III)
7. Uveitis Mid Stage Products (Phase II)
8. Uveitis Early Stage Products (Phase I)
9. Uveitis Preclinical Stage Products
10. Uveitis Therapeutics Assessment
11. Uveitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Uveitis Key Companies
14. Uveitis Key Products
15. Uveitis Unmet Needs
16 . Uveitis Market Drivers and Barriers
17. Uveitis Future Perspectives and Conclusion
18. Uveitis Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Healthcare Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Healthcare Pipeline Analysis: https://www.delveinsight.com/consulting/pipeline-assessment-services
• Hepatic Encephalopathy Market: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-market
• Immunologic Deficiency Syndrome Market: https://www.delveinsight.com/report-store/immunologic-deficiency-syndrome-market
• Menorrhalgia Market Size: https://www.delveinsight.com/report-store/menorrhalgia-market
• Neurofibromatosis 2 Market: https://www.delveinsight.com/report-store/neurofibromatosis-type-2-market-insight
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acanthamoeba Keratitis Market: https://www.delveinsight.com/report-store/acanthamoeba-keratitis-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
• Adult Onset Still Disease Market: https://www.delveinsight.com/report-store/adult-onset-still-disease-market
• Advanced Hepatocellular Carcinoma With Cpb Liver Cirrhosis Market: https://www.delveinsight.com/report-store/advanced-hepatocellular-carcinoma-with-cpb-liver-cirrhosis-market-insight
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arteriovenous Fistula Market: https://www.delveinsight.com/report-store/arteriovenous-fistula-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/merger-and-acquisition
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveitis Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies by DelveInsight | Active Biotech AB, Eyevensys, Alumis Inc, Eli Lilly and Company, Tarsier Pharma here
News-ID: 3723982 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Uveitis
Uveitis Market : An Overview Report
Introduction:
Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye. It can lead to vision impairment or even blindness if left untreated. Uveitis is categorized into different types, including anterior, intermediate, posterior, and panuveitis, depending on the part of the eye affected. The condition can be caused by infections, autoimmune diseases, or trauma. With increasing cases of autoimmune disorders and infectious diseases, the prevalence of uveitis…
Uveitis Treatment Market Size, Share | Trend 2030
Exclusive Report by Ameco Research: Uveitis Treatment Market Size Projected to Reach USD 2 Billion by 2030, Growing at 6% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Uveitis Treatment Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality market research…
Uveitis - Drug Pipeline Landscape, 2022
New York, Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of…
Uveitis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of uveitis based…
Japan Industry Statistics of Uveitis Treatment
Global Uveitis Treatment Market: Overview
Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked. Patients afflicted by uveitis are often referred to an expert after much delay on account of less awareness about the eye malady. This delays timely diagnosis and results in irreversible damage to various ocular structures.
Read Report Overview: https://www.transparencymarketresearch.com/uveitis-treatment-market.html
As per Cochrane,…
Uveitis Treatment Market Analysis of Top industry Scenario
Global Uveitis Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).
According to a new report published by Allied Market Research, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy &…
